CA2159350A1 - Modified oligonucleotides having improved anti-influenza activity - Google Patents
Modified oligonucleotides having improved anti-influenza activityInfo
- Publication number
- CA2159350A1 CA2159350A1 CA002159350A CA2159350A CA2159350A1 CA 2159350 A1 CA2159350 A1 CA 2159350A1 CA 002159350 A CA002159350 A CA 002159350A CA 2159350 A CA2159350 A CA 2159350A CA 2159350 A1 CA2159350 A1 CA 2159350A1
- Authority
- CA
- Canada
- Prior art keywords
- influenza
- oligonucleotide
- gene
- phosphorothioate
- oligonucleotide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4075293A | 1993-03-31 | 1993-03-31 | |
US08/040,752 | 1993-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2159350A1 true CA2159350A1 (en) | 1994-10-13 |
Family
ID=21912738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002159350A Abandoned CA2159350A1 (en) | 1993-03-31 | 1994-03-30 | Modified oligonucleotides having improved anti-influenza activity |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0693123A1 (zh) |
JP (1) | JPH08510900A (zh) |
CN (1) | CN1124980A (zh) |
AU (1) | AU6527094A (zh) |
CA (1) | CA2159350A1 (zh) |
NZ (1) | NZ263985A (zh) |
WO (1) | WO1994023028A2 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69425903T2 (de) * | 1993-12-09 | 2001-02-15 | Thomas Jefferson University Ph | Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen |
US6608035B1 (en) | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
AU5325696A (en) * | 1995-04-03 | 1996-10-23 | Hybridon, Inc. | Method of modulating gene expression without depleting compl ement |
US6372427B1 (en) | 1995-04-12 | 2002-04-16 | Hybridon, Inc. | Cooperative oligonucleotides |
WO1997038097A1 (en) * | 1995-04-12 | 1997-10-16 | Hybridon, Inc. | Cooperative oligonucleotides |
GB9511720D0 (en) * | 1995-06-09 | 1995-08-02 | Isis Innovation | Oligonucleotide phosphorylation method and products |
US5969117A (en) * | 1995-08-17 | 1999-10-19 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotide |
US5652356A (en) * | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US7074768B2 (en) | 1995-08-17 | 2006-07-11 | Idera Pharmaceuticals, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US6624293B1 (en) | 1995-08-17 | 2003-09-23 | Hybridon, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US5886165A (en) * | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
US6958239B2 (en) | 1996-11-21 | 2005-10-25 | Oligos Etc Inc. | Three component chimeric antisense oligonucleotides |
CA2283626A1 (en) * | 1997-03-12 | 1998-09-17 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
GB9710044D0 (en) * | 1997-05-16 | 1997-07-09 | Innes John Centre Innov Ltd | A plant disease resistance signalling gene: materials and methods relating thereto |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
EP1478656B1 (en) | 2002-02-01 | 2009-09-16 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
CA2627585A1 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
AU2009293658A1 (en) | 2008-09-22 | 2010-03-25 | James Cardia | Reduced size self-delivering RNAi compounds |
WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
CN105131067B (zh) | 2010-03-24 | 2019-02-19 | 雷克西制药公司 | 皮肤与纤维化症候中的rna干扰 |
US10934550B2 (en) | 2013-12-02 | 2021-03-02 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer |
CA2932753A1 (en) | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
EP3188799B1 (en) | 2014-09-05 | 2022-07-06 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
JP6983752B2 (ja) | 2015-07-06 | 2021-12-17 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | スーパーオキシドディスムターゼ1(sod1)を標的とする核酸分子 |
WO2017007825A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
JP2018531037A (ja) | 2015-10-19 | 2018-10-25 | アールエックスアイ ファーマシューティカルズ コーポレーション | 長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
DE3907562A1 (de) * | 1989-03-09 | 1990-09-13 | Bayer Ag | Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
JPH06501843A (ja) * | 1990-08-14 | 1994-03-03 | アイシス・ファーマシューティカルス・インコーポレーテッド | アンチセンスオリゴヌクレオチドによるインフルエンザa型ウイルス,アン・アーバh2n2株の阻害 |
-
1994
- 1994-03-30 CN CN94192300A patent/CN1124980A/zh active Pending
- 1994-03-30 CA CA002159350A patent/CA2159350A1/en not_active Abandoned
- 1994-03-30 JP JP6522317A patent/JPH08510900A/ja active Pending
- 1994-03-30 AU AU65270/94A patent/AU6527094A/en not_active Abandoned
- 1994-03-30 WO PCT/US1994/003454 patent/WO1994023028A2/en not_active Application Discontinuation
- 1994-03-30 NZ NZ263985A patent/NZ263985A/en unknown
- 1994-03-30 EP EP94912901A patent/EP0693123A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1994023028A3 (en) | 1995-02-16 |
CN1124980A (zh) | 1996-06-19 |
EP0693123A1 (en) | 1996-01-24 |
WO1994023028A2 (en) | 1994-10-13 |
NZ263985A (en) | 1997-07-27 |
JPH08510900A (ja) | 1996-11-19 |
AU6527094A (en) | 1994-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2159350A1 (en) | Modified oligonucleotides having improved anti-influenza activity | |
US5929226A (en) | Antisense oligonucleotide alkylphosphonothioates and arylphospohonothioates | |
EP0649467B1 (en) | Self-stabilized oligonucleotides as therapeutic agents | |
CA2140649C (en) | Hybrid oligonucleotide phosphorothioates | |
EP0677056B1 (en) | Oligonucleotide alkylphosphonates and alkylphosphonothioates | |
US6143881A (en) | Hybrid oligonucleotide phosphorothioates | |
EP0451221B1 (en) | Chimeric dna-rna catalytic sequences | |
US5532130A (en) | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides | |
CA2266748C (en) | Three component chimeric antisense oligonucleotides | |
US6013639A (en) | G cap-stabilized oligonucleotides | |
US6015886A (en) | Oligonucleotide phosphate esters | |
Cohen | Antisense oligodeoxynucleotides as antiviral agents | |
EP0763050B1 (en) | Branched oligonucleotide as pathogen-inhibitory agents | |
WO1994002498A9 (en) | Hybrid oligonucleotide phosphorothioates | |
CA2154358A1 (en) | Integrated oligonucleotides | |
JPH06511155A (ja) | ギャップを有する2′修飾オリゴヌクレオチド | |
JP2003012688A (ja) | オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
AU781297B2 (en) | Chimeric DNA/RNA ribozymes containing propanediol | |
Cramer et al. | Nucleotides LXIV [1]: Synthesis, hybridization and enzymatic degradation studies of 2′-O-methyl-oligoribonucleotides and 2′-O-methyl/deoxy gapmers | |
EP1574572B1 (en) | Compounds for hydrolysing ribonucleic acids (RNAs) | |
CA2490644A1 (en) | Hybrid oligonucleotide phosphorothioates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |